ABSTRACT
Objective To evaluate liver surgery (liver resection,liver transplantation,liver trauma) in patients with perioperative application of recombinant human growth hormone (rhGH) efficacy and safety.Methods We searched China biomedical literature database (CBM) and relevant randomized controlled Wanfang medicine,PubMed,Cochrane Library and Embase database to January 2018,application of rhGH for patients with liver surgery in rhGH,with placebo or blank control.According to certain criteria,the literatures were excluded and analyzed by RevMan 5.3 software.Results Total of 13 articles and 525 patients were included.The results showed that rhGH can improve the serum albumin (Alb),prealbumin (PA),transferrin (TF) synthesis [WMD =2.42,95％CI (0.45,4.40),P＜0.05;WMD =28.44,95％CI (17.70,39.17),P＜0.05;WMD=0.52,95％CI (0.44,0.61),P＜0.05];high level of CD4/CD8 [WMD =0.40,95％CI (0.22,0.58),P＜0.05];reduce the infection rate [RR=0.49,95％CI (0.31,0.77),P＜0.05];shorten the hospitalization time [WMD=-3.19,95％CI (-5.77,-0.61),P＜0.05];and will not increase the acute rejection and tumor recurrence rate,but need more exogenous insulin to control blood glucose.Conclusion Patients with perioperative application of rhGH can improve the nutrition status and immune function,reduce the rate of infection,promote the rehabilitation of patients,shorten the hospitalization time,and will not increase the acute rejection and tumor recurrence rate.